- Home
- MURA vs RPTX Comparison
MURA vs RPTX Comparison
Compare MURA & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- RPTX
- Stock Information
- Founded
- MURA 2013
- RPTX 2016
- Country
- MURA Ireland
- RPTX Canada
- Employees
- MURA N/A
- RPTX N/A
- Industry
- MURA
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- RPTX Health Care
- Exchange
- MURA Nasdaq
- RPTX Nasdaq
- Market Cap
- MURA 67.4M
- RPTX 54.0M
- IPO Year
- MURA N/A
- RPTX 2020
- Fundamental
- Price
- MURA $4.05
- RPTX $1.29
- Analyst Decision
- MURA Strong Buy
- RPTX Strong Buy
- Analyst Count
- MURA 5
- RPTX 3
- Target Price
- MURA $16.00
- RPTX $7.00
- AVG Volume (30 Days)
- MURA 135.3K
- RPTX 232.9K
- Earning Date
- MURA 03-25-2025
- RPTX 03-03-2025
- Dividend Yield
- MURA N/A
- RPTX N/A
- EPS Growth
- MURA N/A
- RPTX N/A
- EPS
- MURA N/A
- RPTX N/A
- Revenue
- MURA N/A
- RPTX $66,524,000.00
- Revenue This Year
- MURA N/A
- RPTX $12.15
- Revenue Next Year
- MURA N/A
- RPTX N/A
- P/E Ratio
- MURA N/A
- RPTX N/A
- Revenue Growth
- MURA N/A
- RPTX 18.19
- 52 Week Low
- MURA $2.87
- RPTX $1.10
- 52 Week High
- MURA $5.62
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- MURA 51.01
- RPTX 47.52
- Support Level
- MURA $4.13
- RPTX $1.13
- Resistance Level
- MURA $4.39
- RPTX $1.37
- Average True Range (ATR)
- MURA 0.25
- RPTX 0.09
- MACD
- MURA -0.02
- RPTX 0.04
- Stochastic Oscillator
- MURA 42.50
- RPTX 57.14
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.